Werner Scheuer | AMiner学者主页

全面呈现 [Werner Scheuer] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

暂无数据

论文（153）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1Supplementary Figure 4 from Apoptosis Imaging for Monitoring DR5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively

Thomas G. Weber,Franz Osl,Anja Renner,Thomas Pöschinger,Stefanie Galbán,Alnawaz Rehemtulla,Werner Scheuer

PDF file - 186KB, Supplementary Figure 4 - Antibody penetration is enhanced in U87-Luc and U251 brain xenograft tumors indicating BBB disruption.

2023

引用

AI阅读

2Supplementary Figure 2 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast,Christian Klein,Werner Scheuer,Romi Raemsch,Erica Lorenzon,Dirk Bernicke,Frank Herting,Sidney Yu,Huynh Hung The,Laurent Martarello,Christian Gassner,Kay-Gunnar Stubenrauch,

PDF file 188K, Cross-reactivity and binding affinities of A2V CrossMab and the comparator molecules bevacizumab and LC06

2023引用：1

引用

AI阅读

3Supplementary Figure Legends 1-2 from Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

Werner Scheuer,Thomas Friess,Helmut Burtscher,Birgit Bossenmaier,Josef Endl,Max Hasmann

Supplementary Figure Legends 1-2 from Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

2023

引用

AI阅读

4Supplementary Table S3 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Peter Brünker,Katharina Wartha,Thomas Friess,Sandra Grau-Richards,Inja Waldhauer,Claudia Ferrara Koller,Barbara Weiser,Meher Majety,Valeria Runza,Huifeng Niu,Kathryn Packman,Ningping Feng,

FAP-drozitumab antibody-mediated apoptosis does not correlate with DR5.

2023

引用

AI阅读

5Supplementary Methods from Apoptosis Imaging for Monitoring DR5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively

Thomas G. Weber,Franz Osl,Anja Renner,Thomas Pöschinger,Stefanie Galbán,Alnawaz Rehemtulla,Werner Scheuer

PDF file - 63KB, Fluorescence imaging - Fluorescence imaging was used for monitoring anti-DR5-Cy5 distribution in the mouse. Cell culture and cell inoculation of U87-Luc and U251 cell lines - U87-Luc and U251 were used for additional BBB penetration studies and were inoculated as described for D54-Caspase-3/7 GloSensor cell line.

2023

引用

AI阅读

6Supplementary Table 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast,Christian Klein,Werner Scheuer,Romi Raemsch,Erica Lorenzon,Dirk Bernicke,Frank Herting,Sidney Yu,Huynh Hung The,Laurent Martarello,Christian Gassner,Kay-Gunnar Stubenrauch,

PDF file 52K, An overview of the antibodies used in the present study

2023

引用

AI阅读

7Supplementary Figure S4 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Peter Brünker,Katharina Wartha,Thomas Friess,Sandra Grau-Richards,Inja Waldhauer,Claudia Ferrara Koller,Barbara Weiser,Meher Majety,Valeria Runza,Huifeng Niu,Kathryn Packman,Ningping Feng,

FAP-drozitumab BsAb induces tumor growth inhibition in vivo.

2023

引用

AI阅读

8Supplementary Figure 3 from Apoptosis Imaging for Monitoring DR5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively

Thomas G. Weber,Franz Osl,Anja Renner,Thomas Pöschinger,Stefanie Galbán,Alnawaz Rehemtulla,Werner Scheuer

PDF file - 936KB, Supplementary Figure 3 - Apoptosis and fluorescence imaging reveal that 3.9-7.0% of anti-DR5-Cy5 given i.v. reaches subcutaneous D54-Caspase-3/7 GloSensor tumors.

2023

引用

AI阅读

9Supplementary Figure Legends from Apoptosis Imaging for Monitoring DR5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively

Thomas G. Weber,Franz Osl,Anja Renner, Thomas Pöschinger,Stefanie Galbán,Alnawaz Rehemtulla,Werner Scheuer

2023

引用

AI阅读

10Supplementary Figure 3 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast,Christian Klein,Werner Scheuer,Romi Raemsch,Erica Lorenzon,Dirk Bernicke,Frank Herting,Sidney Yu,Huynh Hung The,Laurent Martarello,Christian Gassner,Kay-Gunnar Stubenrauch,

PDF file 201K, A2V CrossMab characterization and safety profile

2023

引用

AI阅读

11Supplementary Figure 1 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast,Christian Klein,Werner Scheuer,Romi Raemsch,Erica Lorenzon,Dirk Bernicke,Frank Herting,Sidney Yu,Huynh Hung The,Laurent Martarello,Christian Gassner,Kay-Gunnar Stubenrauch,

PDF file 169K, Schematic representation of Ang2-VEGF-A CrossMab (RO5520985) and binding properties

2023

引用

AI阅读

12Supplementary Figure 5 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast,Christian Klein,Werner Scheuer,Romi Raemsch,Erica Lorenzon,Dirk Bernicke,Frank Herting,Sidney Yu,Huynh Hung The,Laurent Martarello,Christian Gassner,Kay-Gunnar Stubenrauch,

PDF file 138K, Ex vivo mode of action analysis of Ang-2-VEGF-A inhibition

2023

引用

AI阅读

13Supplementary Figure 1 from Apoptosis Imaging for Monitoring DR5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively

Thomas G. Weber,Franz Osl,Anja Renner,Thomas Pöschinger,Stefanie Galbán,Alnawaz Rehemtulla,Werner Scheuer

PDF file - 75KB, Supplementary Figure 1 - Highly sensitive apoptosis imaging allows tumor detection and randomization at early time points.

2023

引用

AI阅读

14Supplementary Figure S2 and Table S4 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Peter Brünker,Katharina Wartha,Thomas Friess,Sandra Grau-Richards,Inja Waldhauer,Claudia Ferrara Koller,Barbara Weiser,Meher Majety,Valeria Runza,Huifeng Niu,Kathryn Packman,Ningping Feng,

Figure S2. Related to Figure 3. In vitro characterization of the FAP-DR5 BsAb RG7386; Table S4. Characterization of RG7386 binding avidities.

2023

引用

AI阅读

15Supplementary Figure 6 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast,Christian Klein,Werner Scheuer,Romi Raemsch,Erica Lorenzon,Dirk Bernicke,Frank Herting,Sidney Yu,Huynh Hung The,Laurent Martarello,Christian Gassner,Kay-Gunnar Stubenrauch,

PDF file 135K, Analysis of hypoxia during Ang-2-VEGF-A inhibition

2023

引用

AI阅读

16Supplementary Figure 2 from Apoptosis Imaging for Monitoring DR5 Antibody Accumulation and Pharmacodynamics in Brain Tumors Noninvasively

Thomas G. Weber,Franz Osl,Anja Renner,Thomas Pöschinger,Stefanie Galbán,Alnawaz Rehemtulla,Werner Scheuer

PDF file - 414KB, Supplementary Figure 2 - Fluorescence imaging after i.v. application of anti-DR5-Cy5 shows no specific antibody accumulation in the right brain hemisphere.

2023

引用

AI阅读

17Supplementary Figure 7 from Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

Yvonne Kienast,Christian Klein,Werner Scheuer,Romi Raemsch,Erica Lorenzon,Dirk Bernicke,Frank Herting,Sidney Yu,Huynh Hung The,Laurent Martarello,Christian Gassner,Kay-Gunnar Stubenrauch,

PDF file 69K, Ang-2 induced VEGFR-2 upregulation

2023

引用

AI阅读

18Supplementary Figure S1, Table S1, and Table S2 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

Peter Brünker,Katharina Wartha,Thomas Friess,Sandra Grau-Richards,Inja Waldhauer,Claudia Ferrara Koller,Barbara Weiser,Meher Majety,Valeria Runza,Huifeng Niu,Kathryn Packman,Ningping Feng,

Figure S1. Related to Figure 1. Characterization of FAP-drozitumab BsAbs and antitumor efficacy in the presence of FAP-expressing fibroblasts in in vitro co-culture models; Table S1. BsAb binding to DR5 and FAP antigens; Table S2. Anti-tumor efficacy of FAP-drozitumab bispecific molecules is FAPdependent.

2023

引用

AI阅读

19Supplementary Figure S3 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis